Gregg Eure, MD, FACS, Urology of Virginia, discusses the increased of heart failure associated with medications for the treatment of patients with benign prostatic hyperplasia (BPH). A recently published study showed an increased risk of cardiac failure in men with BPH and exposure to 5-alpha reductase inhibitors and/or α-blockers.
Academic, private practice urologists collaborate to change BPH reimbursement
April 1st 2024"We really aimed to affect 3 different contraindications and instead achieved retirement of the entire policy, which, we think, really opens up this wonderful technology to literally hundreds of thousands more patients across the country," says Arpeet Shah, MD.